ID
12665
Description
MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger
Keywords
Versions (2)
- 12/8/15 12/8/15 -
- 7/23/16 7/23/16 -
Uploaded on
December 8, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Adalimumab/Ustekinumab Psoriasis MIPSO EudraCT 2014-003022-40
Adalimumab/Ustekinumab Psoriasis MIPSO EudraCT 2014-003022-40
- StudyEvent: ODM
Description
Medication Adalimumab/Ustekinumab
Similar models
Adalimumab/Ustekinumab Psoriasis MIPSO EudraCT 2014-003022-40
- StudyEvent: ODM